Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

P2130000

Piroxicam

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

4-Hydroxy-2-methyl-3-(pyrid-2-yl-carbamoyl)-2H-1,2-benzothiazine 1,1-dioxide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C15H13N3O4S
CAS Number:
36322-90-4
Molecular Weight:
331.35
MDL number:
MFCD00057317
UNSPSC Code:
41116107
PubChem Substance ID:
329820119
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

piroxicam

manufacturer/tradename

EDQM

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CN1C(C(=O)Nc2ccccn2)=C(O)c3ccccc3S1(=O)=O

InChI

1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)

InChI key

QYSPLQLAKJAUJT-UHFFFAOYSA-N

Gene Information

human ... PTGS1(5742) , PTGS2(5743)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Piroxicam EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Cyclooxygenase inhibitor.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Related product

Product No.
Description
Pricing

1544508

Piroxicam, United States Pharmacopeia (USP) Reference Standard

Y0001475

Piroxicam for system suitability, European Pharmacopoeia (EP) Reference Standard

BP463

Piroxicam, British Pharmacopoeia (BP) Reference Standard

1544541

Piroxicam Related Compound D, United States Pharmacopeia (USP) Reference Standard

1544574

Piroxicam Related Compound G, United States Pharmacopeia (USP) Reference Standard

1544600

Piroxicam Related Compound J, United States Pharmacopeia (USP) Reference Standard

1544520

Piroxicam Related Compound B, United States Pharmacopeia (USP) Reference Standard

1544519

Piroxicam Related Compound A, United States Pharmacopeia (USP) Reference Standard

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

hcodes

H301,H373

Hazard Classifications

Acute Tox. 3 Oral - STOT RE 2 Oral

target_organs

Gastrointestinal tract

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Wanwadee Luksurapan et al.
Archives of physical medicine and rehabilitation, 94(2), 250-255 (2012-10-16)
To compare the effects of phonophoresis of piroxicam (PhP) and ultrasound therapy (UT) in patients with mild to moderate, symptomatic knee osteoarthritis (OA). A randomized, double-blind, controlled trial. Department of rehabilitation medicine, university hospital. Patients with knee OA (N=46; mean
Andres Lust et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 48(1-2), 47-54 (2012-10-23)
The aim of this study was to gain understanding about the effects of different solid-state forms of a poorly water-soluble piroxicam on drug dissolution and oral bioavailability in rats. Three different solid-state forms of piroxicam were studied: anhydrate I (AH)
Jian X Wu et al.
Journal of pharmaceutical sciences, 102(3), 904-914 (2012-12-06)
Several factors with complex interactions influence the physical stability of solid dispersions, thus highlighting the need for efficient experimental design together with robust and simple multivariate model. Design of Experiments together with ANalysis Of VAriance (ANOVA) model is one of
Xin-Yue Song et al.
Talanta, 100, 153-161 (2012-11-13)
A novel design of carbon nanotubes reinforced hollow fiber solid/liquid phase microextraction (CNTs-HF-SLPME) was developed to determine piroxicam and diclofenac in different real water samples. Functionalized multi-walled carbon nanotubes (MWCNTs) were held in the pores of hollow fiber with sol-gel
Michael A Kron et al.
Clinical and vaccine immunology : CVI, 20(2), 276-281 (2012-12-21)
The therapeutic effects of a controlled parasitic nematode infection on the course of inflammatory bowel disease (IBD) have been demonstrated in both animal and human models. However, the inability of individual well-characterized nematode proteins to recreate these beneficial effects has
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service